Immune Therapeutics, Inc. | Business Contracts

Consulting Agreement, dated November 1, 2022, between Immune Therapeutics, Inc. and Glen Farmer (Filed With SEC on November 9, 2022)

Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd (Filed With SEC on October 12, 2022)

Convertible Promissory Note in the Principal Amount of $200,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

[REVISED CYTOCOM AGREEMENT] (Filed With SEC on August 16, 2021)

Consulting Agreement, dated November 1, 2022, between Immune Therapeutics, Inc. and Kelly O. Wilson (Filed With SEC on November 9, 2022)

Separation and Release Agreement, dated July 19, 2022, between Kevin Phelps and Immune Therapeutics, Inc (Filed With SEC on July 22, 2022)

Convertible Promissory Note in the Principal Amount of $100,000, dated July 19, 2022, between Immune Therapeutics, Inc. and Kevin Phelps (Filed With SEC on July 22, 2022)

Term Sheet (Filed With SEC on July 7, 2022)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on March 18, 2022)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on March 18, 2022)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on March 18, 2022)

Letter of Intent, dated May 25, 2021 (Filed With SEC on June 2, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Robert J. Dailey (Filed With SEC on May 24, 2021)

Promissory Note dated March 11, 2021 between Immune Therapeutics, Inc., and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Exchange Agreement dated March 31, 2021 between Immune Therapeutics, Inc. and Global Reverb Corporation and Robert J. Dailey (Filed With SEC on May 24, 2021)

Note Assignment dated November 10, 2020 between Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Note Purchase Agreement dated November 10, 2020 entered into by Iliad Research and Trading, L.P. and Global Reverb Corporation (Filed With SEC on May 24, 2021)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 15, 2021)

Agreement dated August 12, 2020 between Immune Therapeutics, Inc. and Cytocom, Inc. assigning all of .Immune Therapeutics right, title and interest in LDN and MENK in Developing... (Filed With SEC on November 16, 2020)

Amendment to the Articles of Incorporation filed February 5, 2020 approving a reverse split of issued and outstanding shares of common stock by 1,000 to 1 (Filed With SEC on August 14, 2020)

Amendment to the Articles of Incorporation filed March 12, 2020 approving an increase in authorized shares of common stock from 500,000,000 to 750,000,000 (Filed With SEC on August 14, 2020)

Short-form Executive Employment Agreement dated July 22, 2020 (Filed With SEC on July 27, 2020)

Board Resolution dated July 24, 2020 (Filed With SEC on July 27, 2020)

Amendment to Articles of Incorporation filed with the State of Florida on February 6, 2020, together with the Corporate Resolution of the Board of Directors dated February 2, 2020... (Filed With SEC on June 29, 2020)

Securities Purchase Agreement dated as of May 4, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of $53,000 (Filed With SEC on June 29, 2020)

Securities Purchase Agreement dated as of June 15, 2020 with Geneva Roth Remark Holdings, Inc, together with Exhibit A Convertible Promissory Note in the principal amount of... (Filed With SEC on June 29, 2020)

Amendment to Articles of Incorporation filed with the State of Florida on March 12, 2020, 2020 (Filed With SEC on June 29, 2020)

PRC Amendment to The Second Amendment to the License Agreement effective December 31, 2018 with Cytocom, Inc. and signed May 12, 2020 (Filed With SEC on May 14, 2020)

Convertible Promissory Note dated March 30, 2020 to Redstart Holdings Corp. in the principal amount of $53,000 (Filed With SEC on May 14, 2020)

License Agreement dated January 15, 2020 with Forte Biotechnology Intl. Corp (Filed With SEC on May 14, 2020)

Second Amendment to License Agreement with Cytocom Inc., effective December 31, 2018 and signed April 8, 2019 (Filed With SEC on May 14, 2020)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 14, 2020)

Mutual Release and Non-Disparagement Agreement effective April 30, 2020 (Filed With SEC on May 5, 2020)

Board Resolution dated April 30, 2020 (Filed With SEC on May 5, 2020)

Letter of Intent dated March 17, 2020 (Filed With SEC on March 20, 2020)

Board Resolution (Filed With SEC on February 19, 2020)

Employment Agreement with Michael Handley (Filed With SEC on September 25, 2019)

Second Amendment to License Agreement by and between: Cytocom Inc. and Immune Therapeutics Inc., signed April 8, 2019 (Filed With SEC on May 20, 2019)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on May 20, 2019)

Letter to Shareholders (Filed With SEC on May 15, 2019)

Promissory Note dated February 27, 2019 to Phoenix Group in the principal amount of $231,478.39 (Filed With SEC on April 16, 2019)

Immune Therapeutics, Inc. (44)